<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438397</url>
  </required_header>
  <id_info>
    <org_study_id>BHC-17782</org_study_id>
    <nct_id>NCT02438397</nct_id>
  </id_info>
  <brief_title>the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin</brief_title>
  <acronym>CGMS</acronym>
  <official_title>Explore the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin in Chinese Type 2 Diabetes by CGMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study objective: to explore the efficacy of acarbose and metformin on glucose
      fluctuations as add on therapy in type 2 diabetes patients inadequately controlled with
      premix insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:Prospective, parallel group, active-control, randomized, open-label.

      Study Organization:Single-center in China. Endocrinology and metabolism department of 6th
      affiliated hospital of Shanghai Jiaotong university Study Population: Type 2 diabetes
      inadequately controlled by premix-insulin therapy,40 patients per arm(acarbose add on/
      metformin add on) both acarbose and metformin are widely used with premix-insulin in clinical
      practice, for the better glucose control and lower hypoglycemia incident.

      Acarbose delay the absorption of digested carbohydrates from the small intestine and thus
      lower both postprandial glucose and insulin levels which sequently improve glucose
      fluctuation Metformin improve the insulin resistance reduce the gluconeogenesis, glucose
      output and thus lower the fasting glucose
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAGE: mean amplitude of glycemic excursion/MODD: mean of daily differences</measure>
    <time_frame>12 weeks after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>metformin+premix insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin:500mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose+premix insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acarbose:100mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>premix insulin</intervention_name>
    <description>Premix-insulin(human insulin or analog) treatment will continue</description>
    <arm_group_label>metformin+premix insulin</arm_group_label>
    <arm_group_label>acarbose+premix insulin</arm_group_label>
    <other_name>human insulin or analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>500 mg tid by Merck</description>
    <arm_group_label>metformin+premix insulin</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>100mg tid by Bayer</description>
    <arm_group_label>acarbose+premix insulin</arm_group_label>
    <other_name>Glucobay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed T2DM patients (WHO, 1999).

          -  Premix Insulin therapy for more than 3 months, the daily dosage of insulin &gt;20IU and
             &lt;1IU/kg

          -  30 ≤Age ≤ 70 years old, male or female

          -  7.0 ≤ HbA1c ≤10.0%

          -  18.5≤ BMI ≤ 35 kg/m2

          -  Written Informed consent

        Exclusion Criteria:

          -  Subject with type 1 diabetes or gestational diabetes mellitus and other specific types
             DM

          -  Those who can not tolerate AGI or who is suffering GI disease

          -  Metformin contradiction

          -  Concomitant 2 oral anti-diabetes medicine, or 1 OAD with maximum dose

          -  Subject with repeated severe hypoglycemia and/or unawareness of hypoglycemia

          -  Known or suspected allergy to trial product(s) or related products

          -  Females of child bearing potential who are pregnant, breast-feeding or have the
             intention of becoming pregnant or not using adequate contraceptive methods throughout
             the trial

          -  Impaired liver function,

          -  Any other clinically significant condition or major systemic diseases, including
             serious coronary heart disease, cardiovascular disease, cancer, TB, acute infection

          -  Uncontrolled hypertension

          -  Concomitant treatment which influences blood glucose

          -  Impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Jia, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>the 6th affiliated hospital of Shanghai Jiaotong university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jian Zhou, doctor</last_name>
    <phone>18930172033</phone>
    <email>zhoujian8337@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the 6th affliliated hospital of Shanghai Jiaotong university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Weiping Jia</investigator_full_name>
    <investigator_title>Professor,chief of endocrinology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

